Amoxapine (Amoxapine) Patent Expiration, LOE Window & CMS Spending

Amoxapine (Amoxapine) by Teva Pharmaceuticals: Multi-Source Generic Molecule, 2 AB generics, $227K 2024 CMS Part D & Medicaid spend, and $1,350 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$227K
2024 Medicare Part D Spend$187K
2024 Medicaid Spend$39K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,350 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.